Figure 1
Relapse-free survival in ITP and AIHA patients after low-dose rituximab and alemtuzumab. Relapse-free survival was considered as the period of maintenance of the best response achieved (ie, CR or PR).
Relapse-free survival in ITP and AIHA patients after low-dose rituximab and alemtuzumab. Relapse-free survival was considered as the period of maintenance of the best response achieved (ie, CR or PR).
